Expertise in
1
conditions

Marcia R. Hall

London, ENG, GB 
Expertise in
1
conditions
London, ENG, GB 

Overview

Marcia Hall practices practicing medicine in London, United Kingdom.

Ms. Hall is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ovarian Cancer, Agranulocytosis, Osteoarthritis, Orchiectomy, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 128 peer reviewed articles and participating in 8 clinical trials.

Gender

Female

Locations

London, ENG, United Kingdom
Other Locations
Glasgow, SCT G514TF, United Kingdom
Mount Vernon Hospital, Middlesex, ENG, United Kingdom
Uxbridge, United Kingdom
Mount Vernon Cancer Centre
Northwood, ENG, United Kingdom
Kingston Lane, Uxbridge, Kingston Upon Thames, ENG UB38PH, United Kingdom
Hillingdon, ENG, United Kingdom
Leeds, ENG LS29JT, United Kingdom
Roslin, SCT EH259RG, United Kingdom
Nottingham, ENG, United Kingdom
Mount Vernon Cancer Centre, Mount Vernon, SCT, United Kingdom
Regents Court, 30 Regent Street, Sheffield, ENG S14DA, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, TAK228
Study Phase: Phase 2
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Enrollment Status: Unknown
Publish Date: April 12, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: Olaparib, Cediranib, Paclitaxel
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

128 Total Publications

Where can we improve? An evaluation of discrepancies between radiology resident and consultant reports for noncontrast head computed tomography (NCHCT) scans in the emergency department at a tertiary care centre.
Where can we improve? An evaluation of discrepancies between radiology resident and consultant reports for noncontrast head computed tomography (NCHCT) scans in the emergency department at a tertiary care centre.
Journal: Clinical radiology
Published: November 12, 2025

Frequently Asked Questions about Marcia R. Hall

Is Marcia R. Hall a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Marcia R. Hall is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marcia R. Hall participate in research or clinical trials?

Yes. Marcia R. Hall has published 128 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Marcia R. Hall's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hall's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile